Why the study?
Does alpha-ANP reduce fetal inflow pressure in human isolated perfused placenta pre-constricted by NOLA or U46619?
Does alpha-ANP reduce fetal inflow pressure in human isolated perfused placenta pre-constricted by NOLA or U46619?
alpha-ANP attenuates vasoconstriction in the human placenta, but only at concentrations higher than those typically found in fetal or maternal plasma.
Alpha-ANP attenuates placental vasoconstriction only at supraphysiologic concentrations; leaves open relevance to in vivo fetal perfusion.
In order to examine the effect of alpha-ANP on fetal placental vascular tone, single placental lobules were bilaterally perfused and fetal inflow pressure recorded. The placental vasculature was sub-maximally pre-constricted by infusion of the nitric oxide synthase inhibitor N omega-nitro-L-arginine (NOLA) or the thromboxane A2-mimetic U46619. In the presence of continuous infusion of 59.3 mumol/l NOLA, producing a mean pressure increase of 43.7 +/- 1.7 mmHg (n = 8, mean +/- SEM), alpha-ANP (10.7 to 325 nmol/l) produced significant pressure decreases (P < 0.05). In separate experiments (U46619 was either infused at concentrations (4.8 to 21.4 nmol/l) to produce a mean pressure increase (50.1 +/- 2.6 mmHg, n = 10) similar to that produced by NOLA infusion or was infused at a concentration (28.5 nmol/l) that produced a significantly higher pressure increase (104 +/- 15 mmHg), infusion of 1 mumol/l alpha-ANP significantly reduced perfusion pressure. However, 100 nmol/l alpha-ANP or less had no significant effect (n = 4-7). These results indicate that alpha-ANP attenuates NOLA-induced and U46619-induced vasoconstriction in the human placenta, but at concentrations higher than those in fetal or maternal plasma.
No takes yet. Share an insight, caveat, or question.
Stebbing et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: